tradingkey.logo

tradingkey.logo
怜玢


First Tracks Biotherapeutics Ord Shs

TRAX
りォッチリストに远加
47.100USD
-1.600-3.29%
終倀 11-13 16:00ET
1.98B時䟡総額
0.00盎近12ヶ月PER

First Tracks Biotherapeutics Ord Shsに぀いお 䌁業名

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The Company's clinical-stage pipeline includes Rosnilimab, a selective pathogenic T cell depleter, for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator. Rosnilimab is an IgG1 antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. Rosnilimab is designed to selectively deplete pathogenic T cells while sparing non-pathogenic T cells, including naive T cells, to preserve overall immune function and restore immune homeostasis. Its molecules have applicability across a range of autoimmune and inflammatory diseases, including gastroenterology, rheumatology and other areas.

First Tracks Biotherapeutics Ord Shs プロフィヌル


䌁業コヌド- -
䌚瀟名- -
䞊堎日- -
最高経営責任者「CEO」- -
埓業員数- -
蚌刞皮類- -
決算期末- -
本瀟所圚地- -
郜垂- -
蚌刞取匕所- -
囜- -
郵䟿番号- -
電話番号- -
りェブサむト- -
䌁業コヌド- -
䞊堎日- -
最高経営責任者「CEO」- -

First Tracks Biotherapeutics Ord Shsの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.02M
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
37.65K
-292.53%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
19.19K
-319.15%
Mr. John A. Orwin
Mr. John A. Orwin
Independent Chairman of the Board
Independent Chairman of the Board
17.89K
-310.79%
Mr. Benjamin Stone
Mr. Benjamin Stone
Chief Business Officer
Chief Business Officer
17.26K
-1094.95%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
15.96K
-456.93%
Dr. Dennis M. Fenton, Ph.D.
Dr. Dennis M. Fenton, Ph.D.
Independent Director
Independent Director
10.99K
-915.41%
,
,
--
--
Mr. Ajim Tamboli
Mr. Ajim Tamboli
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Paul Lizzul, M.D., Ph.D.
Dr. Paul Lizzul, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.02M
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
37.65K
-292.53%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
19.19K
-319.15%
Mr. John A. Orwin
Mr. John A. Orwin
Independent Chairman of the Board
Independent Chairman of the Board
17.89K
-310.79%
Mr. Benjamin Stone
Mr. Benjamin Stone
Chief Business Officer
Chief Business Officer
17.26K
-1094.95%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
15.96K
-456.93%

よくある質問

First Tracks Biotherapeutics Ord Shsの䞊䜍5名の株䞻は誰ですか


First Tracks Biotherapeutics Ord Shsの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Daniel R. Faga
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。